Home / Equities / ASX200 slide continues

ASX200 slide continues

Equities

ASX200 slide continues, tech darlings under pressure, Altium (ASX:ALU) revenue falls, weaker open ahead

The ASX200 (ASX:XJO) couldn’t hold sustain early gains, falling another 0.3% on Tuesday with the financial sector the only real positive.

National Australia Bank (ASX:NAB) lead the sector higher adding 1.1% as signs of higher bond rates are likely to support higher net interest margins.

  • Selling pressure continued to build on the technology sector after Altium Ltd (ASX:ALU) reported a 3% fall in first half revenue as challenging conditions in the US and China put an ‘unprecedented drag’ on sales of the company’s chip design software.

    This came as a surprise given the huge demand for processing power and incredible shift to digital platforms throughout 2020; shares finished 2.2% as a result.

    Four wheel driver accessory distributor ARB Corporation (ASX:ARB) offered a positive surprise, with the company capitalising on the ‘holiday at home’ trend reporting a 21.6% increase in sales compared to 2019 levels, sending revenue to $284 million for the first half. Management now expect profit of between $70 and $72 million, shares finished 5.8% higher.

    Whilst a positive result the company is now doubled in value in less than 12 months and now trades on a valuation similar to a fast-growing tech company; this may be a stretch given the potential of a return to normal travel in 2021.

    Origin Energy (ASX:ORG) goes renewable, Avita Medical (ASX:AVH) jumps 15.3%

    Origin Energy (ASX:ORG) announced plans to develop a 700MW battery at their Eraring coal-fired power station, Australia’s largest, in an effort to reduce pressure on the ailing electricity grid and likely cut the costs associated with their ageing asset.

    Avita Medical (ASX:AVH), a favourite of fund managers and brokers alike for its special burns’ treatments jumped 15.3% after reporting revenue of USD$5 million in the second quarter of 2021 from its primary RECELL treatment and USD$5.1 million in total global revenue, an increase of 57% on 2019 levels.

    The company, whose shares are down over 60% over the last 12 months, reported a 9% decrease in their cash holdings as the struggle to gain traction in major hospitals.

    Similarly, Polynovo (ASX:PNV) fell 13.0% despite reporting a 31% increase in sales in the first half despite slower than expected sales in October and November.

    The company is showing strong progress with a number of large hospitals signing purchase orders and the group reporting 89% growth in trading accounts throughout 2020.

    Both these results evidence the incredibly difficult task for biotech companies to bring innovative products to market on commercial terms.

    US stocks pause ahead of earnings season, Trump impeachment commenced, social sell off continues

    The value shift continued in US markets overnight, with the energy and financial sectors gaining most, sending the Dow Jones up 0.2%, with the Nasdaq also adding 0.3%.

    The primary driver was more positives on the supply side of oil markets with US shale producers confirming their intention not to increase production in an oversupplied market, sending the oil price to a ten month high above USD$50 per barrel.

    Major oil names including BP (NYSE:BP) and Chevron Inc. (NYSE:CVX) who added 2.6% and 1.9%.

    E-commerce business Etsy (NASDAQ:ETSY) rallied another 12.1%, as the reseller of vintage and handmade goods is expected to report a strong final quarter.

    Consumers and investors seem to be responding to censorship decision made by the likes of Amazon (NASDAQ:AMZN) and Twitter (NASDAQ:TWTR), both falling another 2.0%.

    The US Congress plans to vote on a second impeachment of President Trump, which is mostly symbolic given the short-time before his term ends next week.

    Drew Meredith

    Drew is publisher of the Inside Network's mastheads and a principal adviser at Wattle Partners.




    Print Article

    Related
    Investors shake off home bias, shift to international equities

    Australian investors are looking past the allure of franking credits and moving towards more unbiased diversification, with ETFs providing a cheap, liquid and highly available access point.

    Tahn Sharpe | 4th Nov 2024 | More
    ‘Still weak’: Listed asset managers need to evolve rapidly to escape ETF obliteration

    With traditional equity managers losing the fight against passive product providers, diversification into more specialist classes of asset management may provide a more sustainable path. But that’s a pricey endeavour, and easier said than done.

    Tahn Sharpe | 28th Oct 2024 | More
    Ex-20 option shines as banks and miners face growth headwinds in 2025 and beyond

    The entrenched position of the banks and miners in the ASX 200 doesn’t necessarily correlate to inherent growth potential, especially with the issues both sectors face into. For investors, it may be worth considering an alternative path broad market exposure.

    Tahn Sharpe | 4th Oct 2024 | More
    Popular
  • Popular posts: